South African HIV Investment Case

Research Themes: Costs, Cost-Effectiveness and Benefits of HIV Care and Treatment

Since 2016, annual updates of the HIV Investment Case set out to determine the optimal package of HIV interventions in South Africa, with the aim improve allocative efficiency of HIV funding from the three main sources- the South African government, PEPFAR and the Global Fund. The 2021 HIV Investment Case had the following central additions: For the 95% retention scenario in, we included a hypothetical ART retention intervention that aimed at reaching the UNAIDS target of 95% ART coverage. We also added an optimised package of HIV self-test distribution models, based on our previous work on the cost-effectiveness of HIV self-testing.

Principal Investigator/ Program Director Dr Gesine Meyer-Rath
Start date2016
End date
StatusOngoing

Funded by

Publications

HE2RO staff involved

Dr Gesine Meyer-Rath Lise Jamieson Dr. Jacqui Miot

Stay up to date

Receive newsletters and keep up to date with developments at HE2RO.